Advancing the Treatment Paradigm for mCRPC: Insights into Combination Therapy and Future Directions : Episode 10
Opinion
Video
Addressing Remaining Unmet Needs in mCRPC
Author(s):
Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.
Video Player is loading.
Video content above is prompted by the following:
- What is one key unmet need or clinical utility in the treatment of mCRPC that future trials should address?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
The ADVANCED-2 trial, TARA-002
Unmet needs in high risk NMIBC
Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans
The Current Landscape of ADT in Prostate Cancer
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Approaching Corticosteroid Selection With Abiraterone in Patients With High-Risk Localized or Locally Advanced Prostate Cancer
Incorporating Micronized Abiraterone and Low-Fat Meal Dosing: Monitoring Efficacy and Tolerability
The Growing Call for Combination Therapy in NMIBC Treatment
Related Content
